Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Revolution Medicines (RVMD) Amortization of Deferred Charges (2020 - 2025)

Revolution Medicines has reported Amortization of Deferred Charges over the past 3 years, most recently at $11.9 million for Q4 2025.

Quarterly results put Amortization of Deferred Charges at $11.9 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $23.4 million (up 1299.1% YoY), and the annual figure for FY2025 was $24.2 million, changed.
Amortization of Deferred Charges for Q4 2025 was $11.9 million at Revolution Medicines, up from $11.4 million in the prior quarter.
Over the last five years, Amortization of Deferred Charges for RVMD hit a ceiling of $11.9 million in Q4 2025 and a floor of $691000.0 in Q3 2021.